FDA warns doctors to stop using heart pump tied to deaths
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 03/06/2021 (1905 days ago), so information in it may no longer be current.
WASHINGTON (AP) — U.S. health regulators warned surgeons Thursday to stop implanting a heart pump made by Medtronic due to power failures recently tied to cases of stroke and more than a dozen deaths.
Medtronic said earlier in the day it would stop selling its Heartware assist device, which is intended to boost blood circulation in patients with heart failure.
Recent company data showed the device can unexpectedly stop working and sometimes fail to restart, the Food and Drug Administration said. The company said it hasn’t been able to pinpoint the root cause in every case.
Surgeons can use implants from other manufacturers, the FDA said in a memo to physicians.
About 4,000 people worldwide currently have the Medtronic device, roughly half of them in the U.S. For those patients, the agency said U.S. doctors should contact the company for the latest guidance on managing the device, which includes managing blood pressure.
The FDA said Medtronic halted sales after reviewing 100 reports of power failures with the device, which led to 14 patient deaths and 13 patients having it removed. The company previously issued recalls on some Heartware devices and components used when implanting it. In December, the company warned about power failures or delayed restarts with three lots.
The company said patients should not automatically have the device removed. Taking out recalled heart implants has to be carefully weighed against the potential risks of surgery. Medtronic said in a statement physicians should decide “on a case-by-case basis, considering the patients clinical condition and surgical risks.” The company said it is preparing a guide for managing patients “who may require support for many years.”
The Heartware device was used for heart failure patients awaiting transplant or as a permanent implant for those who weren’t healthy enough for that procedure. The device helps strengthen one of the heart’s lower chambers needed for adequate blood circulation.
Medtronic is one of the world’s largest medical device and equipment makers, selling thousands of implants used to treat heart, neurological and joint conditions.
___
The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
